Search

Additional file 1. Figure S1. The treatment schema. The consolidation therapy included RIF (60 mg/kg daily in an oral divided dose) in a 4-week-on and 4-week-off regimen for 4 cycles and ATRA (25 mg/m2 daily in an oral divided dose) in a 2-week-on and 2-week-off regimen for 7 cycles. Of note, treatment cycles were counted according to the cycles of ATRA. Figure S2. Flow chart of participants enrollment, treatment and follow-up. 54 patients were enrolled in the clinical trial and an intention-to-treat analysis were performed. Seven patients had major protocol violation. Four of them suffered cerebral hemorrhage in induction therapy, so their physicians advised two cycles of chemotherapy for consolidation therapy and continued with RIF plus ATRA for 7 cycles. One of them changed protocol for a grade 3 hematochezia. One patient returned to his hometown hospital and changed his treatment plan. The last one did not give a specific reason for the change in treatment. Another seven patients were in consolidation process. Two patients were lost to follow-up and one of them had not completed the trial. Thus 39 patients were included in the per-protocol analysis. Figure S3. PML-RARA tested at 3, 5 and 7 months from the beginning of the induction therapy in ITT analysis.Table S1. Characteristics of the Patients. Table S2. Clinical characteristics and treatment of five patients with cerebral hemorrhage. Table S3. Treatment and outcomes of two relapsed patients. Patient No.1 had cerebral hemorrhage at the time of diagnosis. She had a molecular relapse at 11 months after remission and a central nervous system relapse at 13 months. Patient No.2 had a hematologic relapse at 13 months and achieved remission again after RIF plus ATRA reinduction and alive until last follow-up.